Home » May / June 2023 » Synthetic Chemistry in Nucleic Acid Drugs Recent progress in bridged nucleic acids (BNA)
2023 | May / June 2023

Synthetic Chemistry in Nucleic Acid Drugs Recent progress in bridged nucleic acids (BNA)

by cyb2025
K. Okano
Bridged nucleic acid
nucleic acid drug
nucleotide
oligonucleotide
Peer Reviewed

KAZUYA OKANO
Deputy General Manager, Juzen Chemical Corporation, Tokyo, Japan

ABSTRACT

The number of approved nucleic acid drugs has increased recently owing to progress in the medicinal chemistry of oligonucleotide therapeutics; the expansion of drug sales is providing new API demand opportunities for CDMO. Nucleic acid drugs utilize various chemically modified nucleotides, to avoid decomposition by nucleases in the human body and improve the RNA binding affinity. The production of modified nucleotides requires organic synthesis technology and sufficient production capacity at CDMO. This study focuses on the synthetic process of modified nucleotides, especially those comprising bridged nucleic acids (BNAs), and explains the progress in BNA research from a process chemistry perspective.

INTRODUCTION

ABOUT THE AUTHOR

Kazuya Okano – After working at Mitsubishi Petrochemical Corporation, Mitsubishi Chemical Corporation, API Corporation, Rockwood Lithium Japan and Albemarle Japan, currently the Deputy General Manager of the Tokyo Office of Juzen Chemical Corporation.
Engaged in various chemical industry operations such as organic synthesis research, process chemistry, fine chemical business and CDMO business.
Associate Professional Engineer, Chemistry (As.P.E.Jp)

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login